Tumour immunology – Maries van den Broek Combination of immune checkpoints – John Haanen Discussion - Oncoletter, Webportal für Onkologie und onkologische Hämatologie mit integrierten Links zu Wikipedia und Pharma Wiki sowie NCI, Kompendium, Medline und wichtigen Kongressen wie ASCO, ASH, SABCS, ESMO, EHA, Darmkrebs, Nierenkrebs, Brustkrebs, Prostatakrebs

Startseite

Kongressberichte & Archiv

Archiv 2017

Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium

Essentials of tumour immunology and immunotherapies

Essentials of tumour immunology and immunotherapies

– Maries van den Broek: Tumour immunology

– John Haanen: Combination of immune checkpoints

– Discussion

News

CAR T for R/R multiple myeloma with idecabtagene vicleucel (ide-cel) resubmitted to FDA.

03-08-2020 13:16

MORE INFO

Atezolizumab approved by FDA in combination with cobimetinib & vemurafenib in BRAF V600+ melanoma.

03-08-2020 13:09

MORE INFO

Tafasitamab-cxicx approved in combination with lenalidomide in adult R/R diffuse large B-cell lymphoma (DLBCL).

03-08-2020 12:54

MORE INFO

Osimertinib, an irreversible EGFR-TKI, granted breakthrough therapy designation by FDA as an adjuvant treatment for Sage Ib/II/IIIA EGFR-mutated NSCLC after complete tumor resection.

03-08-2020 12:51

MORE INFO

Alpelisib, a PI3K inhibitor, approved by the European Commission to treat HR+/ HER2-negative advanced/metastatic breast cancer with a PIK3CA mutation who progressed on endocrine therapy.

03-08-2020 12:48

MORE INFO

Pevonedistat, an NAE inhibitor, granted breakthrough therapy designation by FDA for higher-risk MDS.

03-08-2020 12:44

MORE INFO

Bispecific HER2/3 antibody zenocutuzumab granted orphan drug status by FDA for pancreatic cancer.

03-08-2020 12:40

MORE INFO

ADP-A2M4, a treatment for synovial sarcoma, granted PRIME status by the EMA.

03-08-2020 12:14

MORE INFO

Ventana, HER2 Dual ISH DNA Probe Cocktail assay approved by FDA as a companion diagnostic for trastuzumab.

03-08-2020 12:11

MORE INFO

Essentials of tumour immunology and immunotherapies

– Maries van den Broek: Tumour immunology

– John Haanen: Combination of immune checkpoints

– Discussion

News

CAR T for R/R multiple myeloma with idecabtagene vicleucel (ide-cel) resubmitted to FDA.

Atezolizumab approved by FDA in combination with cobimetinib & vemurafenib in BRAF V600+ melanoma.

Tafasitamab-cxicx approved in combination with lenalidomide in adult R/R diffuse large B-cell lymphoma (DLBCL).

Osimertinib, an irreversible EGFR-TKI, granted breakthrough therapy designation by FDA as an adjuvant treatment for Sage Ib/II/IIIA EGFR-mutated NSCLC after complete tumor resection.

Alpelisib, a PI3K inhibitor, approved by the European Commission to treat HR+/ HER2-negative advanced/metastatic breast cancer with a PIK3CA mutation who progressed on endocrine therapy.

Pevonedistat, an NAE inhibitor, granted breakthrough therapy designation by FDA for higher-risk MDS.

Bispecific HER2/3 antibody zenocutuzumab granted orphan drug status by FDA for pancreatic cancer.

ADP-A2M4, a treatment for synovial sarcoma, granted PRIME status by the EMA.

Ventana, HER2 Dual ISH DNA Probe Cocktail assay approved by FDA as a companion diagnostic for trastuzumab.

Newsletter